Communiqués SinoMab BioScience Limited

Actions

3681

HK0000544194

Marché Fermé - Hong Kong S.E. Autres places de cotation 10:08:07 05/07/2024			Varia. 5j.	Varia. 1 janv.
1,64 ^HKD	-2,38%		-2,38%	-2,38%

13/06	Les actions de Hong Kong rebondissent alors que les données sur l'inflation américaine sont inférieures aux prévisions	MT
13/06	Sinomab Bioscience administre la première dose d'un médicament contre la dermatite atopique	MT

Communiqués

Débloquez toutes les actualités sur toutes les entreprises : Ne manquez plus une opportunité d'investissement rentable !

Inscription 100% Gratuite

SinoMab BioScience preclinical results of SM17 on atopic dermatitis (AD) published on International Scientific Journal Allergy	16/04	AQ
SinoMab's IND Application of SM17 has once again Received Approval from NAMP	12/09/23	AQ
SinoMab Announces that IND Application of SM17 for the Treatment of Asthma was Approved by NAMP	14/08/23	AQ
SinoMab Annouces IND Application of SM17 for the Treatment of Asthma was Accepted by NMPA CDE	22/05/23	AQ
SinoMab Awarded the "Most Valuable Pharmaceutical and Medical Company" in the Selection of the "7th Hong Kong Golden Stocks Awards"	19/12/22	AQ
SinoMab Announces Appointment of Mr. Shanchun WANG as the President (China) of the Company	04/11/22	AQ
Everest Medicines Receives Approval of Investigational New Drug Application from China NMPA for EVER001, a Novel BTK Inhibitor in Development for Treatment of Renal Diseases	27/09/22	AQ
Sinomab Announces IND Application of SN1011 for the Treatment of Neuromyelitis Optica Spectrum Disorder Approved by NMPA	24/08/22	AQ
SinoMab Received the Highest Subsidy from HKSTP	08/07/22	AQ
The Mechanism of Action of SinoMab's Flagship Product SM03 is Successfully Published in the Journal of Immunology, a Reputable Journal on Immunology in the U.S.	21/06/22	AQ
SinoMab Dosed First Healthy Subject in Phase I Clinical Trial of SM17 in the U.S.	15/06/22	AQ
SinoMab Announces IND APPLICATION FOR SN1011 ACCEPTED BY NMPA CDE	09/06/22	AQ
SinoMab Announces IND APPLICATION FOR SN1011 APPROVED BY NMPA	20/04/22	AQ
IND Application for SinoMab's First-in-Class Asthma Therapeutic Product SM17 Approved by FDA	14/03/22	AQ
SinoMab BioScience : DATE OF BOARD MEETING	09/03/22	PU
IND Application for SinoMab's First-in-Class Asthma Therapeutic Product SM17 Accepted by FDA	17/02/22	AQ
SinoMab Announces IND APPLICATION FOR SN1011 ACCEPTED BY NMPA CDE	07/02/22	AQ
SinoMab Awared the "Best Small and Mid-Cap Company" and "Best CEO" in the Selection of the "6th Hong Kong Golden Stocks Awards" and the "Listed Company with the Most Growth Potential" in the Selection of "2021 Sina Finance Golden Unicorn Best Hong Kong and US Listed Companies"	11/01/22	AQ
SinoMab Announces the Completion of Enrollment in Phase III Clinical Trial in China for its Flagship Product, SM03	30/11/21	AQ
SinoMab Was Invited to Attend the Inaugural Asia Summit on Global Health	26/11/21	AQ

Aucun résultat pour cette recherche

Toute l'actualité Reco analystes Faits marquants Insiders Transcripts Communiqués Publications officielles Autres langues Idées de trading Articles Zonebourse Analyses Zonebourse

Communiqués SinoMab BioScience Limited

Actions

3681

HK0000544194

Communiqués

Filtres